This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           July 16, 2014

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store

 

Roche: FDA grants Avastin in cervical cancer priority review
Reuters
Swiss drugmaker Roche said U.S. health regulators have granted a priority review of its Avastin drug when combined with chemotherapy to treat women with cervical cancer. An approval by the U.S. Food and Drug Administration for treating advanced cervical cancer would open another large market for the medicine in patients for whom chemotherapy has been largely ineffective.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




MORCELLATION


FDA panel recommends informed consent, labeling changes to address morcellator risk
ACS Surgery News
A requirement for informed consent outlining the risks of morcellation of unsuspected malignancies in women treated with laparoscopic power morcellators for presumably benign fibroids was among the recommendations made by a Food and Drug Administration advisory panel. On July 11, the second day of a two-day meeting of the FDA's Obstetrics and Gynecology Devices Advisory Committee, panelists also supported adding a boxed warning to the labels of laparoscopic power morcellators.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


VIDEO: 'Improve — but do not abandon — power morcellation'
The Oncology Report
Without power morcellation, the number of hysterectomies performed using an open approach would dramatically increase — and the combined mortality from laparoscopic hysterectomy and potential dissemination of leiomyosarcoma would be less than that of open hysterectomy, according to testimony given July 11 at a Food and Drug Administration expert panel meeting.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
 


FDA advisory panel voices concern about morcellation risk
Medscape (Free login required)
A U.S. Food and Drug Administration advisory panel has voiced support for greater restrictions on the use of laparoscopic power morcellators (LPMs) in uterine fibroid surgery, while leaving the door open for industry to create safer devices. On July 11, the second day of a 2-day meeting, the Obstetrics and Gynecology Devices Advisory Committee answered specific questions from the FDA about how the agency might address the newly appreciated risk that when LPMs are used to remove presumably benign fibroids during minimally invasive procedures, the morcellation process could inadvertently disseminate unsuspected malignant tissue, resulting in the "upstaging" of the tumor and worsening of the patient's prognosis.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


  FEATURED COMPANIES
Work for the best
We are seeking a gyn-oncologist to join our growing health system in Springfield, Mo. Our clinic has on-site lab and radiology services, access to a da Vinci® surgical robot and a strong support staff. For more information about this opportunity at our physician owned and operated clinic, call 1-800-869-4201. MORE
Exceptional Care, Close to Home

21st Century Oncology – the nation’s largest cancer treatment network and global leader in cancer care – providing integrated clinical teams treating patients collaboratively to improve outcomes.
MORE


OVARIAN CANCER


Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer
Clinical Cancer Research
Findings in a study in the July 15 issue of Clinical Cancer Research suggest the presence of a productive and potentially restricted antitumor B-cell response in basal-like breast and immunoreactive ovarian cancers. Immunomodulatory therapies that support B-cell responses may be a promising therapeutic approach to targeting these B-cell infiltrated tumors.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Bloodstream: New route for ovarian cancer spread
Science 2.0
Circulating tumor cells spread ovarian cancer through the bloodstream, homing in on a sheath of abdominal fatty tissue where it can grow and metastasize to other organs, according to a study published in the July 14 issue of Cancer Cell. Researchers found the circulating tumor cells (CTCs) rely on HER3 to find their way to the omentum. HER3's heavy presence on these cells makes it a biomarker candidate and suggests possible therapeutic options to thwart ovarian cancer progression, the researchers noted.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


HPV VACCINE


Cervical cancer vaccine doesn't boost clot risk: Study
HealthDay News via U.S. News & World Report
Concerns that the human papillomavirus vaccine may increase the risk of serious blood clots seem unfounded, a new study says. The study of half a million Danish women who received the HPV vaccine, which protects against cervical cancer and other health problems, found no link between the shots and the formation of blood clots known as venous thromboembolisms. In the U.S. it's called the Gardasil vaccine.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


HEALTH POLICY


The biggest changes in health care
U.S. News & World Report
The hospital industry continues to evolve, streamlining and improving patient care, integrating big data and moving from a fee-for-service to a fee-for-outcome payment model. The hospitals of yesterday were quite different from the sprawling health care centers that are common in the U.S. today. Here's a look at how the industry has changed.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

July 9, 2014
July 2, 2014
June 25, 2014
June 11, 2014






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063